Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

This study has been completed.
Information provided by (Responsible Party):
Cangene Corporation Identifier:
First received: July 23, 2008
Last updated: October 30, 2013
Last verified: October 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2013
  Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)